# Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer

> **NCT00363766** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 52 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** LY573636-sodium

## Key facts

- **NCT ID:** NCT00363766
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-10
- **Final completion:** 2008-10
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2018-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00363766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00363766, "Study of LY573636-Sodium in Patients With Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00363766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*